Related Experiment Video

Updated: Jan 30, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

Francesco Schettini1, Irene De Santo1, Carmen G Rea1

  • 1University of Naples Federico II, Naples, Italy.

Frontiers in Oncology
|January 12, 2019
PubMed

Insights

Cyclin-dependent kinase (CDK) 4/6 inhibitors show promise beyond breast cancer. These agents are being evaluated as single therapies for various advanced solid tumors.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDK) 4/6 inhibitors (abemaciclib, palbociclib, ribociclib) target cell cycle progression.
  • These inhibitors, combined with endocrine agents, improve outcomes in HR+ HER2- metastatic breast cancer (MBC).

Purpose of the Study:

  • To review the biological, preclinical, and clinical data on CDK4/6 inhibitors as single agents in advanced solid tumors.

Main Methods:

  • Review of preclinical studies in cell cultures and mouse models.
  • Analysis of ongoing Phase I, II, and III clinical trials evaluating CDK4/6 inhibitors in monotherapy.

Main Results:

  • CDK4/6 inhibitors demonstrate activity against a wide range of solid tumors, including liposarcoma, rhabdomyosarcoma, non-small cell lung cancer, glioblastoma multiforme, esophageal cancer, and melanoma.
  • Abemaciclib is currently the only approved single-agent CDK4/6 inhibitor for pretreated HR+ HER2- MBC.

Conclusions:

  • CDK4/6 inhibitors exhibit potential as monotherapy in various solid tumors.
  • Further clinical evaluation is ongoing to establish their role as single-agent treatments in advanced cancers.
Keywords:
abemaciclibcell cyclecyclin-dependent kinasespalbociclibribociclibsolid tumors

More Related Videos

Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

3.3K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
667
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
575
Metallic Solids02:37

Metallic Solids

Metallic solids such as crystals of copper, aluminum, and iron are formed by metal atoms. The structure of metallic crystals is often described as a uniform distribution of atomic nuclei within a “sea” of delocalized electrons. The atoms within such a metallic solid are held together by a unique force known as metallic bonding that gives rise to many useful and varied bulk properties.
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
20.6K
Structures of Solids02:22

Structures of Solids

Solids in which the atoms, ions, or molecules are arranged in a definite repeating pattern are known as crystalline solids. Metals and ionic compounds typically form ordered, crystalline solids. A crystalline solid has a precise melting temperature because each atom or molecule of the same type is held in place with the same forces or energy. Amorphous solids or non-crystalline solids (or, sometimes, glasses) which lack an ordered internal structure and are randomly arranged. Substances that...
17.7K
Network Covalent Solids02:18

Network Covalent Solids

Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K